Literature DB >> 18404135

Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment.

David A Geier1, Elizabeth Mumper, Bambi Gladfelter, Lisa Coleman, Mark R Geier.   

Abstract

BACKGROUND: Many formulations of Thimerosal (49.55% mercury by weight)-containing Rho(D) immune globulins (TCRs) were routinely administered to Rh-negative mothers in the US prior to 2002.
OBJECTIVES: It was hypothesized: (1) if prenatal Rho(D)-immune globulin preparation exposure was a risk factor for neurodevelopmental disorders (NDs) then more children with NDs would have Rh-negative mothers compared to controls; and (2) if Thimerosal in the Rho(D)-immune globulin preparations was the ingredient associated with NDs, following the removal of Thimerosal from all manufactured Rho(D)-immune globulin preparations from 2002 in the US the frequency of maternal Rh-negativity among children with NDs should be similar to control populations.
METHODS: Maternal Rh-negativity was assessed at two sites (Clinic A-Lynchburg, VA; Clinic B-Rockville and Baltimore, MD) among 298 Caucasian children with NDs and known Rh-status. As controls, maternal Rh-negativity frequency was determined from 124 Caucasian children (born 1987-2001) without NDs at Clinic A, and the Rh-negativity frequency was determined from 1,021 Caucasian pregnant mothers that presented for prenatal genetic care at Clinic B (1980-1989). Additionally, 22 Caucasian patients with NDs born from 2002 onwards (Clinics A and B) were assessed for maternal Rh-negativity.
RESULTS: There were significant and comparable increases in maternal Rh-negativity among children with NDs (Clinic: A=24.2%), autism spectrum disorders (Clinic: A=28.3%, B=25.3%), and attention-deficit-disorder/attention-deficit-hyperactivity-disorder (Clinic: A=26.3%) observed at both clinics in comparison to both control groups (Clinic: A=12.1%, B=13.9%) employed. Children with NDs born post-2001 had a maternal Rh-negativity frequency (13.6%) similar to controls.
CONCLUSION: This study associates TCR exposure with some NDs in children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404135

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  7 in total

Review 1.  Environmental factors associated with autism spectrum disorder: a scoping review for the years 2003-2013.

Authors:  M Ng; J G de Montigny; M Ofner; M T Do
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-01       Impact factor: 3.240

Review 2.  Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines.

Authors:  José G Dórea
Journal:  Neurochem Res       Date:  2017-04-24       Impact factor: 3.996

3.  Is dental amalgam safe for humans? The opinion of the scientific committee of the European Commission.

Authors:  Joachim Mutter
Journal:  J Occup Med Toxicol       Date:  2011-01-13       Impact factor: 2.646

4.  Cord blood mercury and early child development: effects of the World Trade Center.

Authors:  José G Dórea
Journal:  Environ Health Perspect       Date:  2009-01       Impact factor: 9.031

Review 5.  Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism.

Authors:  Janet K Kern; Boyd E Haley; David A Geier; Lisa K Sykes; Paul G King; Mark R Geier
Journal:  Int J Environ Res Public Health       Date:  2013-08-20       Impact factor: 3.390

6.  Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to thimerosal and other metal compounds.

Authors:  D A Geier; P G King; M R Geier
Journal:  Toxicol Environ Chem       Date:  2009-06-11       Impact factor: 1.437

Review 7.  Systematic Assessment of Research on Autism Spectrum Disorder (ASD) and Mercury Reveals Conflicts of Interest and the Need for Transparency in Autism Research.

Authors:  Janet K Kern; David A Geier; Richard C Deth; Lisa K Sykes; Brian S Hooker; James M Love; Geir Bjørklund; Carmen G Chaigneau; Boyd E Haley; Mark R Geier
Journal:  Sci Eng Ethics       Date:  2017-12       Impact factor: 3.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.